Crohn's & colitis 360 · 2026
The association between 6-thioguanine nucleotide levels, adalimumab exposure, immune response, and drug clearance.
Письмо в редакциюНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yarur Andres, Lo Jonathan C, Abraham Bincy, Hanauer Stephen, Dervieux Thierry
Аннотация
BACKGROUND: Thiopurines are associated with improved infliximab pharmacokinetics (PK), but their impact on adalimumab PK and immunogenicity is not well defined. This study examined associations between 6-thioguanine (6-TGN) levels and antibodies to adalimumab (ATA), adalimumab drug levels (ADL), and adalimumab clearance (CL).
METHODS: Using a large clinical laboratory database, we included adults with Crohn's disease or ulcerative colitis treated with thiopurines and adalimumab who had RBC 6-TGN and adalimumab concentrations measured within 30 days. ATA, ADL, and CL were assessed using drug-tolerant assays and nonlinear mixed-effects modeling. A 6-TGN threshold of ≥125 pmol/8 × 108 RBCs was used. Logistic regression was performed to calculate odds ratios (ORs).
RESULTS: We analyzed 1194 specimens from 1100 patients; ATA positivity was 3.7%. Compared with 6-TGN ≥125 pmol/8 × 108 RBCs, lower 6-TGN was associated with higher odds of ATA formation (>1.7 U/mL; OR = 2.55), lower odds of ADL ≥10 µg/mL (OR = 0.58), and lower odds of low CL (< 0.318 L/d; OR = 0.55). Compared with every-other-week dosing, weekly dosing produced higher ADL (13.1 vs 8.9 µg/mL; P < .01) but also higher CL (0.425 vs 0.302 L/d; P < .01). Within each dosing interval, higher 6-TGN levels were associated with lower prevalence of ATA (P < .05) and a higher chance of achieving ADL ≥10 µg/mL (P < .01) and CL < 0.318 L/d (P < .01).
CONCLUSION: Higher 6-TGN levels are associated with reduced immunogenicity, higher adalimumab drug levels, and lower clearance. Thiopurine may enhance adalimumab PK and support a more favorable therapeutic response.
METHODS: Using a large clinical laboratory database, we included adults with Crohn's disease or ulcerative colitis treated with thiopurines and adalimumab who had RBC 6-TGN and adalimumab concentrations measured within 30 days. ATA, ADL, and CL were assessed using drug-tolerant assays and nonlinear mixed-effects modeling. A 6-TGN threshold of ≥125 pmol/8 × 108 RBCs was used. Logistic regression was performed to calculate odds ratios (ORs).
RESULTS: We analyzed 1194 specimens from 1100 patients; ATA positivity was 3.7%. Compared with 6-TGN ≥125 pmol/8 × 108 RBCs, lower 6-TGN was associated with higher odds of ATA formation (>1.7 U/mL; OR = 2.55), lower odds of ADL ≥10 µg/mL (OR = 0.58), and lower odds of low CL (< 0.318 L/d; OR = 0.55). Compared with every-other-week dosing, weekly dosing produced higher ADL (13.1 vs 8.9 µg/mL; P < .01) but also higher CL (0.425 vs 0.302 L/d; P < .01). Within each dosing interval, higher 6-TGN levels were associated with lower prevalence of ATA (P < .05) and a higher chance of achieving ADL ≥10 µg/mL (P < .01) and CL < 0.318 L/d (P < .01).
CONCLUSION: Higher 6-TGN levels are associated with reduced immunogenicity, higher adalimumab drug levels, and lower clearance. Thiopurine may enhance adalimumab PK and support a more favorable therapeutic response.